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Abstract The aims were to explore the effects and health economic consequences of patient education in patients
with COPDin a12-month follow-up. Sixty-two patients withmild-to-moderate chronic obstructive pulmonary disease
(COPD) were at our outpatient clinic randomly allocated to an intervention group or a control group.The intervention
group participated in a 4-h schooling, followed by one-to-two individual nurse and physiotherapist consultations. Self-
management was emphasized following a stepwise treatment plan.Effectivenesswas expressed in terms of proportions
inneed ofgeneralpractitioner (GP) consultations, patient satisfaction andutilization of rescuemedication.Doctor visits,
days off work, dispensed pharmaceuticals, hospital admissions, travel costs, educational and time costswere recorded.
The control and intervention groups inducedmean total costs of NOK19 900 and10 600 per patient, respectively.The
resultswere robustto realistic changes inthe assumptionsuponwhichtheywere based.Forevery NOKput into patient
education, therewas a saving of 4.8.The NNEtomake one patient independentof their GP was1.7 (95% CI:1.3--2.8) and
associatedwith a concomitant savingofNOK15800.The correspondingNNEtomakeoneperson satisfiedwiththeir GP
was 4.5 (95%CI:2.9--10) andNOK41900, respectively.Areducedneedof100DDDofrescuemedicationwas associated
with a concomitant savingof NOK5600.We conclude thatpatienteducation of patientswith COPDin a12-month follow-
up improvedpatientoutcomes andreduced costs.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1293, available online athttp://www.idealibrary.comon
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COPD is both chronic and incurable. The outcome of
treatment can therefore only be measured through
changes in the degree of disease activity. In the absence
of cure, treatment is directed towards reducing the fre-
quency and severity of acute exacerbations andminimiz-
ing the e¡ect of the disease on the patient’s health.
There has been an increase inmorbidity andmortality
due to chronic obstructive pulmonary disease (COPD)
in the western world (1) over the last few decades. In
Norway in 1972, the prevalence of asthma and COPD
were estimated as 1.4 and 4.1%, respectively, while the
corresponding ¢gures in1988 were 2.3 and 5.4% (2).The
calculated costs (1US=7 NOK, 1994) for asthma and
COPD in Norway (4 million people) regarding hospitali-Received and accepted 2 January 2002.
Correspondence should be addressed to: Frode Gallefoss,
Lungeseksjonen,Medisinsk avdeling,Vest-Agder Sentralsykehus 4604
Kristiansand,Norway.Fax: +47-38 07 33 27; E-mail:
frode.gallefoss@vas.nozations (383 million NOK), absenteeism from work (ex-
cluding sick leaves of duration o2 weeks, 135 million
NOK), and anti-asthmatic medication (533 million
NOK) (3) amounted in1994 to roughly1billion NOK (4).
Thus, the diagnosis and treatment of asthmatics and
patients with COPD put a signi¢cant burden onNorwe-
gian health budgets. The situation was comparable with
other Western countries (5) and the potential for public
savings seemedhigh.
Health care today experiences an increasing gap be-
tweenwhat is medically possible and what is prioritised.
Since each decision to use resources implies a sacri¢ce,
health economical studies are increasingly important
for skilled resource allocations to be made. There is a
need for improved co-operation regarding such alloca-
tion of resources, in order to introduce apparently bet-
ter health care systemsmore readily.Health economical
surveys and trials increase the possibility of improving
the quality of such priority.
The objectives of the present study were to examine
the e¡ect of patient education and self-management on
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cessity for GP visits, patient satisfaction and to perform
cost^bene¢t and cost-e¡ectiveness analyses. Prior to
our study, there were no RCTs available reporting
neither the e¡ect nor the costs of patient education
and self-management on patients with COPD. Such trials
are still lacking.This paper concentrates on the cost as-
pect of patient education and self-management in refer-
ral to previous papers onvarious e¡ectiveness outcomes
from the same trial (6^10).The study was conducted in
the societal perspective, implying that all costs are ac-
counted for, irrespective of who pays.
METHODS
A total of 62 consecutive patients with COPD were in-
cluded in the study between May 1, 1994 and December
1,1995.Before randomization they hadreceived ordinary
consultation care at our outpatient chest clinic at Cen-
tral Hospital of Vest-Agder, Kristiansand, Norway. Eligi-
ble subjectswerepatientswithCOPD,o70 years of age,
not su¡ering from any serious disease.Of the eligible pa-
tients, the inclusion ratewas 91% (62/68).
The patients signed a written consent and were then
randomly assignedusing randomnumber tables supplied
by an external statistician in sealed envelopes.The con-
trol group was followed by their general practitioners
(GPs),while the interventiongroup ¢rstreceived anedu-
cation programme and a self-management plan before
being transferred to a 1-year follow-up by their GPs.
The availability and organization of GP care was similar
in the two treatment groups. Subjects with COPD were
to have an FEV1 equal to or higher than 40% and lower
than 80% of predicted (11). Thirty-two percent showed
20% reversibility to 80mgh ipratropium bromide and/or
400mgh salbutamol (12,13).TABLE 1. The organization of group sessions
Educator Subject
First session Medical doctor Self-care
The componen
Prevention of a
Pharmacist The e¡ectof a
Second session Nurse Review from ¢
Self-assessmen
Treatmentplan
Physiotherapist Respiration du
Rest positions
Relaxation exe
Consciousness
Physical activitEDUCATIONALINTERVENTION
The interventiongroupreceiveda speciallymade19-page
booklet with essential information on asthma/COPD,
medication, self-assessment and self-management. In-
structions in the recording of peak expiratory £ow
(PEF) and symptoms in a diary weregiven.Patient educa-
tion consisted of (2 2)-h group sessions of 5^8 persons
on two separate days1week apart (Table1).
During1^2 individual sessions with a specially trained
nurse the following important issues were emphasized:
K e¡ort was made to establish a partnership with the
patient by using open-ended questions,
K acknowledging concerns and fears about the
obstructive lung disease and providing reassurance,
K essentials of the educational group sessions were
repeatedwith an individual approach,
K checklist was used to cover the important issues,
K the goals of COPD treatment were stated,
K symptoms were noted in an e¡ort to attain
consciousness about early symptoms at
exacerbations,
K individual factors causing attacks/exacerbations
were discussed,
K tobaccoweaning was emphasized,
K fears of adverse e¡ects of medication were
expressed,
K inhalation technique was checked and PEF and
symptomswere discussed.
At the ¢nal teaching, the patients received an indivi-
dual treatmentplan on thebasis of the acquiredpersonal
information and 2 weeks of peak £ow monitoring. The
personal understanding of the treatment plan with
regard to changes in PEF and symptoms was discussed
and tested. All patients received stepwise treatment
plans aimed at making early changes in medication in
the event of exacerbations. Forty-six per cent of thosets of obstruction
ttacks
nti-obstructivemedication onthe components of obstruction
rst session
t and self-management
s in general
ring attacks/exacerbations
rcises
about breathing
yproposals
426 RESPIRATORYMEDICINEeducated (12 of 26) received a standard treatment plan
(7). Non-standard treatment plans, incorporating the
use of oral steroids as the ¢rst line of action in theyellow
zone, were followed in some cases, for example, if the
patient already used high dosages of inhaled steroids as
maintenance therapy, or could report that a double or
triple increase in inhaled steroids previously had shown
amarginal e¡ect on the course of attacks/exacerbations.
Among 14 patients with COPD receiving non-standard
treatment plans, eight patients did not want to or were
not able to use peak £ow monitoring as a basis for
change in medication. For those patients, symptom-
only-based treatment plans were issued.
The individual physiotherapist lessons (1^2 sessions of
40min) concentrated on a practical approach to the to-
pics discussed in the group sessions.
Medicationwas coded to de¢ned daily dosages (DDD)
according to the Anatomical Therapeutic Chemical
(ATC) Classi¢cation Index (14). Short-acting b2-agonist
inhalations were recorded as rescue medication since
they were not recommended for regular use.Dispensed
medication was reported from all local pharmacies
through monthly printouts from the pharmacy compu-
ter records (10). The number of GP-visits and absentee-
ism from work was self-reported at monthly intervals
while days in hospital were both self-reported and
checked against hospital records (7).
Patient satisfactionwith health professions at baseline
and at 12-month follow-up was assessed by a question-
naire based on selected parts from the Omnibus Survey
(15). The answers were blinded for patient identity in
order to receive the highest degree of honesty. The
questions addressed satisfaction with overall handling
of COPD by GP, and agreement or disagreement with
various satisfaction measures (8). The same questions
were asked regarding the pulmonary outpatient clinic.
At the 1-year follow-up the same questions were
answered.
COSTS
The costswerebased onutilization of care andunit costs
(1US=7 NOK,1994). Patient copayments were included
in the costs.Direct costs were de¢ned as costs borne by
the health care system, community and family. Indirect
costs were de¢ned as productivity loss and time
costs borne by the individual, family, society or by the
employer.
The cost ofasthma education included individual costs
paid by all patients (NOK 472) for both group and indivi-
dual sessions, independent of the exact number of indivi-
dual nurse sessions.The reimbursementcosts (NOK160)
were according to the fee schedule of the National
Health Insurance (NHI) covering both group sessions
and individual sessions.The NHI reimbursements for in-dividual physiotherapist sessions were NOK 101 per
session. Market prices were applied for the peak £ow
meter (NOK 207).The average cost of premises was as-
sumed to be NOK45/ patient for group and individual
sessions assuming that the facilities were used for 7.5h/
day at a rate of NOK 1000/m2/year (high standard).
Print costs of the patient brochurewere included (NOK
10/item).
The cost of hospital care for asthma was based on the
NorwegianDiagnosis RelatedGroups (DRG) reimburse-
ment rates (16), assuming that all admissions fell in DRG
Chapter 4, rate number 88 (NOK 21120 per stay).
The monthly GP visit registration forms revealed de-
tailed information ondate, time andduration ofconsulta-
tion, name of the doctor, administered pulmonary
function tests and personal costs by the patient. The
costs were set according to the NHI fee schedule (17).
The public block grant for GP clinics was included, at
the time NOK 365100/year, which, with an average con-
sultation rate of 4010 consultations/year (18), assumed
each patient consultation to amount to NOK 91. Pulmon-
ary consultant visitswere priced according to the NHI fee
schedule (17).
The cost of pharmaceuticals (anti-asthmatics) according
to the ATC Classi¢cation Index, group R03 and H02A B
(14), was based on current marked prices for dispensed
medication as reported monthly from local pharmacies
(6).
The cost of time for those employed was set equal to
the mean national hourly wage rate (NOK 106.2) (19).
Time costs were applied for seeking both health care
and asthma education, assuming 2 and 2.5h (including
waiting and travel time) for GP and pulmonary physician
visits, respectively. Individual educational sessions on the
same day were assumed to last for 1h (plus 1.5h travel
time) including 40min for individual nurse and phy-
siotherapist sessions, and adding 20min of waiting time
per session. The cost of lost leisure for those not em-
ployed was assumed to be zero.The number ofdays ab-
sent from work due to COPD was self-reportedmonthly,
and valued according to the national average daily wage
rate (NOK 567) (19).
Patients’ travel costs in relation to medical care and
asthma medication were calculated on the basis of bus
fares from the patients’ residence.
No discounting was undertaken on costs and conse-
quences due to the short time perspective. One-way
sensitivity analyses on costs were undertaken to explore
how robust the results were to changes in the assump-
tions upon which they were based.The low estimate of
production loss was calculated to be hourly wage-rate
times 70%, with reference to the friction cost method
(20) and the high estimate times130%, thereby including,
for example, social costs (employer tax, etc.).
A cost^ concentration curve shows the cumulative
costs plotted against the cumulative number of patients,
TABLE 2. Baseline characteristics of patients with
COPDincluded inthe study
Control
group
n= 31
Intervention
group
n= 31
Sex, men, n (%) 16 (52) 15 (48)
Age, mean (SD), years 58 (10) 57 (9)
Smokinghabits
Current smokers, n (%) 12 (39) 12 (39)
Pack years, median* 17 17
Ex-smokers, n (%) 19 (61) 15 (48)
Never-smokers, n (%) 4 (13)
Employed, n (%) 16 (52) 14 (45)
FEV1 (forced expiratory
volume in1s)
Mean (SD), litres 1.7 (0.5) 1.8 (0.5)
% predicted, mean (SD) 56 (11) 59 (9)
FVC (forcedvital capacity)
Mean (SD), litres 3.3 (0.9) 3.3 (1.0)
% predicted, mean (SD) 89 (12) 88 (14)
PEF, % predicted, mean (SD) 70 (19) 69 (20)
FEV1%w, mean (SD) 52 (10) 55 (9)
*Medianvalues are employed fornon-normallydistrib-
uted data.
wBased on the question:How long have you had asthma/
COPD symptoms?
w(FEV1/FVC) 100.
ANALYSISOFSELF^MANAGEMENT INPATIENTS 427starting with the patient with highest costs and ending
with the patient with lowest cost.
Cost^bene¢t analyses express both inputs and conse-
quences of di¡erent interventions in monetary units. A
cost^bene¢tratio after patient educationwas calculated
as follows: educational costs+patient time cost for edu-
cational programme/total costs educational costs+pa-
tient time cost for educational programme.
Cost-e¡ectiveness analyses compare competing inter-
ventions in terms of costper unit of clinical e¡ectiveness.
A cost-e¡ectiveness ratio is the di¡erence in costs be-
tween two alternatives dividedby the di¡erence in e¡ec-
tiveness between the same two alternatives (dcosts/d
e¡ects). A positive ratio implies a positive e¡ect at a cer-
tain cost while a negative numerator and a positive de-
nominator imply a positive e¡ect at a lower cost (21).
STATISTICS
Results with skewed distribution, as judged by normality
plots and K^S Lilliefors’ test for normality with Po0.05,
arepresentedwithmedianvalues as ameasure of central
tendency with the 25th and 75th percentiles as a mea-
sure of dispersion (22). Mean values are also displayed
for better interpretation of data. The assumptions and
rationale for the Mann^Whitney U-test and the chi-
square (w2-test) were clari¢ed and discussed in previous
papers. All statistical tests were performed two sided
with a signi¢cance level of 5%.
The concept of number needed to treat (NNT) is the
estimated number of patients who need to be treated
with a new treatment rather than the standard treat-
ment, for one additional patient to bene¢t (23). In this
study, we change the expression to ‘‘number needed to
educate’’ (NNE) (6).NNE is the reciprocal value of abso-
lute risk reduction (ARR) i.e.1/ARR. ARR=PiPc, where
Pi is the proportion with the desirable outcome in the
intervention group and Pc is the proportion in the con-
trol group.
ETHICS
Permission to establish a register of patientswas givenby
the National Data Supervision Centre. The methods
were in accordancewith the ethical standards of theHel-
sinki Declaration as approved by the regional ethical
committee.
RESULTS
Withdrawals
In the intervention group, four patients failed to com-
plete the educational programme. The reasons for not
¢nishing the programme included social problems(n=1), unannounced emigration (n=1), failure to meet
at educational group sessions for unknown reasons
(n=1) and serious myocardial infarction (n=1). Another
patientwaswithdrawn from the studyduring the follow-
up due to lymphoma (n=1).This left us with 26 patients
(81%) for a1-year follow-up.Thepatientswhowerewith-
drawn from the intervention group did not, to our
knowledge, have any serious deterioration in their ob-
structive lung disease, and nonewere hospitalised.
In the control group four patients were withdrawn,
due to lack of co-operation (n=2), diagnosis of rectal
cancer (n=1) and emigration (n=1). Two of the with-
drawn control group patients were hospitalised for ex-
acerbations of their COPD.This left us with 27 patients
(84%) for the1-year follow-up.
The study participants had a mean FEV1at baseline of
57% of predicted (Table 2). Forty-eight per cent were
employed and 39% were current smokers at randomisa-
tion, while 94% had a history of smoking.The mean age
(SD) was 60 (9) years.
Elevenper centdidnotcollect short-acting b2-agonist
inhalations (rescue medication) at the pharmacies with
no apparent di¡erences between treatment groups.
Among those who received rescue medication, the edu-
catedpatients received a median (25th/75th percentiles)
428 RESPIRATORYMEDICINEDDD of 125 (100/344) compared with 290 (150/550) in
the control group (P=0.003) (10).
During the12-month follow-up, approximately 5 times
as many educated patients did not visit their GP com-
paredwithnon-educated (73 vs15%,Po0.001).Themean
reductions in GP consultations for the educated were
85% (from 3.4 to 0.5, Po0.0001), compared with unedu-
cated (7).
At baseline, high proportions of patients were satis-
¢ed with the overall handling of their disease at both
their outpatient clinic (87%) and GP (85%), with no ob-
vious tendency to favour one professional group. At the
1-year follow-up, all educated patients were satis¢ed
with the overall handling of their disease by their GP,
comparedwith 78% in the control group (P=0.023) (8).
The mean direct cost (rounded o¡ to nearest NOK
when presented, but not when calculated) in the edu-
cated COPD group was NOK 9600, the indirect NOK
1100, in total NOK 10 600 (Table 3). The corresponding
costs for the control groupwere NOK14 000, 5900 and
19 900 with no statistically signi¢cant di¡erences. If how-
ever, the costs for GP visits, hospitalisations and absen-
teeism from work were summed, the cost di¡erences
between the groupswere statistically signi¢cant, namely
(mean, SD) NOK12600 (35500) and NOK 2900 (6900),
P=0.003,Mann^Whitney U-test) for the control and in-
tervention groups, respectively.TABLE 3. Direct, indirect and total costs (NOK) per patient d
groups
Cost items Control, n= 27
Mean
(SD)
Median
(25/75
Educationalprogramme 0 0
Peak £owmeter 0 0
Pharmaceuticals 6700 (4400) 5900 (
GP visitw 900 (1400) 300 (2
Pulmonaryphysicianvisitsw 100 (400) 0 (0/0)
Hospital admissions 6300 (21000) 0 (0/0)
Travel costs doctor visits 89 (200) 44 (22
Travel costs educationalprogramme 0
Total direct costs 14 000 (23300) 8100 (3
Patienttime cost for
educationalprogramme
0
Patienttime cost fordoctor visits 500 (1400) 0 (0/20
Production lossw 5500 (20200) 0 (0/0)
Total indirect costs 5900 (21400) 0 (0/40
Total costs 19 900 (38 800) 8100 (3
Both cost items and sums are, if NOK4100, rounded o¡ to ne
* Mann^Whitney U-test.
wMedian values with 25th and 75th percentiles (25/75P) are sho
travel time andwere only calculated for those being employed, b
analysis.Themeannumberof GP visits, pulmonaryphysicianvisit
respectively.The corresponding ¢gures for the intervention grouReduced absenteeism from work in the educated
group explained most of the di¡erence in total costs.
The production loss accounted for 28 and 0.03% of the
total costs in the control and intervention groups, re-
spectively. There was an uneven distribution of costs
(Fig. 1). The most costly patient in the control group
amounted to 33% of the total costs for thewhole group.
The corresponding value for the most costly patient in
the educated group was12%. As can be judged from the
cost^ concentration curve, the fourmost costly patients
in the non-educated and educated groups amounted to
66 and 40%, respectively, of the total group costs.Using
the base case assumptions, the total costs were lower in
the educated group than in the control group.Thus, pa-
tient education incurred lower costs and better out-
comes. If indirect costs were disregarded, the costs
were still lower in the educated group. There were no
overt changes in total cost di¡erences in a one-way sen-
sitivity analysiswhen themostunfavourable assumptions
were chosen for the variables (Table 4).
Themean educational intervention costs including pa-
tient time costs for the educational programme were
(900+700)=NOK 1600. The mean di¡erence in total
costs as (19 90010 600)=NOK 9300, while the bene¢t
inmonetary termswhen adapted for the calculation of a
cost^bene¢t ratio was (9300^1600)=NOK 7700. The
cost^bene¢t ratio for patient education thus becameuring a 12-month follow-up for the intervention and control
Intervention, n= 26 P*
percentiles)
Mean
(SD)
Median
(25/75 percentiles)
900 (200) 1000 (900/900) o0.001
200 o0.001
3900/9000) 5700 (3400) 5200 (2300/9200) 0.618
00/1200) 100 (200) 0 (0/200) o0.001
29 (100) 0 (0/0) 0.636
2400 (6900) 0 (0/0) 0.694
/44) 13 (29) 0 (0/22) o0.001
100 (36) 100 (100/100) o0.001
900/15100) 9600 (8500) 7700 (4100/1100) 1.000
700 (700) 600 (0/1500) o0.001
0) 33 (99) 0 (0/0) 0.007
300 (1300) 0 (0/0) 0.648
0) 1100 (1700) 600 (0/1500) 0.168
900/16 000) 10 600 (8400) 8900 (4500/11800) 0.581
arest NOK100.
wn due to the skewed distribution of data.Time costs include
ut alternative assumptionswere explored through sensitivity
s and days o¡ work in the control groupwere 3.4,0.3 and18.5,
pwere 0.5,0.08 and1.0.
FIG. 1. Cost^concentration curve.
ANALYSISOFSELF^MANAGEMENT INPATIENTS 4291600:7700, meaning that for everyNOKput into patient
education, therewas a saving of 4.8.
A cost-e¡ectiveness analysis (Table 5) revealed that
the NNE to make one patient independent of their GP
was 1.7 (95% CI 1.3^2.8) and associated with a concomi-
tant total cost saving of NOK 15 800. Correspondingly,
the NNE to make one person satis¢ed with their GP
amounted to 4.5 (95% CI 2.9^10) and associated with a
concomitant saving of NOK 41900. A reduced need of
100 DDD of rescue medication was associated with a
concomitant saving of NOK 5600.TABLE 4. One-way sensitivity analyses.Total costchanges (NOK
Variables Range of values
Time cost for those employed NOK/h
Base case 106.2
Low 106.270%
High 106.2130%
Time cost for those not employed NOK/h
Base case 0
Low 106.270%
High 106.2130%
Cost ofeducational programme NOK
Base case 921
Low Teachingcosts
High Teachingcosts 2
Production loss NOK/h
Base case 106.2
Low 106.270%
High 106.2130%
Travel costs NOK
Base case Bus fares
Low 0
High Bus fares 4
‘‘Base case’’ is the assumptions for themain conclusion.‘‘Low’’a
Regarding the educationalprogrammethe amountpaidandreim
of paywasused as a basis.DISCUSSION
We conclude that patient education in COPD in a 12-
month follow-up reduced both direct, indirect and total
costs in the educated group, compared to the non-edu-
cated. For every NOK put into patient education, there
was a saving of 4.8.The NNE to make one patient inde-
pendent of their GPwas1.7 and associatedwith a conco-
mitant saving ofNOK15 800.The correspondingNNE to
make one person satis¢ed with their GP was 4.5 and
NOK 41900, respectively. A reduced need of 100 DDD
of rescuemedicationwas associatedwith a concomitant
saving of NOK 5600.
The ¢rst impressionmightbe thatpatienteducation in
COPD does not seem that e¡ective, especially if com-
paredwith the educated asthma group, which improved
quality of life and FEV1, compared to no education (9).
However, this lack of statistical signi¢cant di¡erences
shouldbe interpretedwith some cautiondue to the small
sample sizes of the COPD treatment groups, although
the overall impression from the data in general is that pa-
tient education alone is not as e¡ective for patients with
COPD as for asthmatics.
The selected e¡ectiveness measures may also be ar-
gued.Firstly, is a ‘‘GP-independent patient with COPD’’ a
desirable outcome? Secondly, is increased satisfaction
with GP after patient education in an out-patient clinic a) per patientunder varyingassumptions
Total costs
Control Intervention Mean di¡erence
Mean (SD) Mean (SD)
19 900 (38 800) 10 600 (8400) 9300
19600 (38 000) 10 400 (8500) 9200
19700 (38100) 10 900 (8500) 8800
9300
20300 (39300) 11200 (8500) 9100
20 600 (39800) 11700 (8600) 8900
9300
19 900 (38 800) 10300 (8400) 9600
19 900 (38 800) 10 800 (8400) 9100
9300
18300 (33700) 10500 (8300) 7800
21500 (44200) 10700 (8500) 10 800
9300
19800 (38 800) 10500 (8400) 9300
20200 (39100) 11100 (8400) 9100
nd ‘‘high’’ indicate low and high estimates for the assumptions.
bursedwasexchangedwiththecostofteachingwhenthe scale
TABLE 5. Cost^e¡ectiveness ratios
Cost-e¡ectiveness ratios Adjusted cost-e¡ectiveness ratios*
Directcosts Total costs Directcosts Total costs
Incremental cost
(NOK)/unit
of improvement
Incremental cost
(NOK)/unit
of improvement
Incremental cost
(NOK)/unit
of improvementw
Incremental cost
(NOK)/unit
of improvementw
Di¡erence inneed for
rescuemedication
(DDD)
4400/165 =27 9300/165 =56 2700/100 5600/100
Cost-e¡ectiveness
ratio/percentof patients having
The costofmaking one personz
Directcosts Total costs Directcostsw Total costsw
GPindependent 4400/48 =92 9300/48 =194 7500 15 800
Satis¢edwith GP 4400/22 =200 9300/22 =423 19800 41900
*An adjustedcost-e¡ectivenessratio relates tothe costperoutcomeofclinical signi¢cance (costperreducedneed forrescue
medication of100 DDD).
wThemain outcome cost-e¡ectiveness ratios (the two columns to the right) are rounded o¡ to nearest NOK100.
zThe costofmaking one personhave = (director total costs di¡erence) (numberneeded to educate)
430 RESPIRATORYMEDICINEdesirable outcome? Third, is reduced dispensed rescue
medication due to less symptoms or increased tolerance
to symptoms? However, although none of these mea-
sures are core estimates in the handling of patients with
COPD,webelieve that they together indicate a desirable
outcome. As previously communicated, all the educated
patients said that they felt ‘‘much safer’’ or ‘‘safer’’ after
patient education (8). In that perspective, the reduced
need for GP and rescue medication most probably indi-
cates a desirable outcome. Increased patient satisfaction
is considered an important issue in the patient^ doctor
relationship. Patient satisfaction may well explain more
of the positive e¡ects of patient education than pre-
viously thought.Gooddiscussions are likely to encourage
positive attitudes, which again are likely to be in£uenced
by patient experience of successful control.
Regarding the cost analysis of patient education in
COPD, the mean di¡erences in cost seemed even larger
than for the asthmatics (6). Production loss seemed of
greatest importance, but hospitalization costs also con-
tributed signi¢cantly to the di¡erence.However, the dis-
tribution of costs was skewed, so that a few costly
patients in each group had a large impact on the average
costs. The di¡erences may therefore easily have been
both larger and smaller. The lack of statistically signi¢-
cant di¡erences in costsmaybe argued.Firstly, this could
also be in£uenced by the small sample size reducing the
power of the trial. Secondly, the cost analyses, not all
costspoint in the same direction.Patientsmay, as a desir-
able behaviour, increase their medication costs to avoid
absenteeism from work or hospitalizations. However,
they increase their total costs by doing so.Hence, in this
way the total cost di¡erence in the two treatmentgroups may close up, but due to di¡erent cost items.
The cost conclusions in the study seem justi¢ed by the
statistically signi¢cant di¡erences between treatment
groups when costs due to non-desirable outcomes (GP
visits, absenteeism fromwork andhospitalisations) were
summed.Thirdly, in cost analyses, statistically signi¢cant
di¡erences are not critical, as themost important factor
is whether the precision around the estimates of costs is
su⁄cient for the decision at hand (24). Thus, sensitivity
analyses were performed testing reasonable low and
high estimates for the assumptions without overt
changes in ourmain conclusions.
The outcomes of both the cost^bene¢t and cost-ef-
fectiveness analyses of patient educationwere powerful.
The cost^bene¢t ratio in this study expresses that
money was used in a reasonable way. In medicine, we
are accustomed to better outcomes at greater costs.
This trial emphasises the power of patient education on
patients with COPD with better outcomes at lower
costs.We have previously shown that patient education
in asthma was also powerful with regard to cost-e¡ec-
tiveness (6).
Interestingly, the mean costs in the control group
aligned fairly wellwith themean total costs in COPDpa-
tients in Sweden as recently communicatedby Jansson et
al. (25).They made telephone interviews of 213 patients
with COPD from a representative cohort with mild,
moderate and severe disease and reported a mean total
cost of approximately 19 000 Swedish Crowns per year.
They reported that for mild COPD, the main cost item
was medication while for moderate and increasingly so
for severe disease, hospitalization costs became the
main cost item.
ANALYSISOFSELF^MANAGEMENT INPATIENTS 431Economic logic is based on the notion of scarcity. As
resources (money) are scarce, each decision to use re-
sources implies a sacri¢ce.This is because onceresources
are used in a certainway, they cannotbe used in an alter-
nativemanner.Thus, health economics allow us to reach
conclusions about the best way to allocate resources.
Health care workers ¢nd themselves asking with in-
creasing frequency as towhich technology shouldbe pri-
vileged and which should not, and up to what point the
need for health care should be met. All such decisions
have to be made in the light of the accountability de-
manded by both the public and founders of health care
systems, regardless of whether they are public or pri-
vate. In this panorama, there are goodreasons for health
care workers to get involved in carrying out economic
evaluations. The involvement of health care workers
should ensure that all dimensions of evaluation are taken
into account in a multidimensional approach, which in-
cludes equity and humanity as well as e¡ectiveness and
economic e⁄ciency.
When a cost-e¡ectiveness analysis reveals better out-
comes at lower costs, a so-called dominant strategy (21),
priority should be simple since it represents a win^win
situation. A trial revealing better health outcome for
the individual at lower cost for the society should be dif-
¢cult to ignore for the e⁄cient decision-maker or politi-
cian. In the meantime, to increase the amount of
evidence, more studies on the cost-e¡ectiveness of pa-
tient education and self-management in asthma and
COPD arewarranted.
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